Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dentsply Sirona (XRAY) Receivables (2016 - 2025)

Dentsply Sirona's Receivables history spans 17 years, with the latest figure at $688.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 23.74% year-over-year to $688.0 million, compared with a TTM value of $688.0 million through Dec 2025, up 23.74%, and an annual FY2025 reading of $688.0 million, up 23.74% over the prior year.
  • Receivables for Q4 2025 was $688.0 million at Dentsply Sirona, up from $654.0 million in the prior quarter.
  • The five-year high for Receivables was $750.0 million in Q4 2021, with the low at $556.0 million in Q4 2024.
  • Average Receivables over 5 years is $659.0 million, with a median of $655.0 million recorded in 2024.
  • Year-over-year, Receivables surged 35.55% in 2021 and then dropped 20.0% in 2024.
  • Tracing XRAY's Receivables over 5 years: stood at $750.0 million in 2021, then fell by 15.73% to $632.0 million in 2022, then increased by 9.97% to $695.0 million in 2023, then decreased by 20.0% to $556.0 million in 2024, then rose by 23.74% to $688.0 million in 2025.
  • Per Business Quant, the three most recent readings for XRAY's Receivables are $688.0 million (Q4 2025), $654.0 million (Q3 2025), and $646.0 million (Q2 2025).